PMID- 28551685
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20170821
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 6
DP  - 2017 Jun
TI  - Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization 
      Using Tissue Microarray in Breast Cancer.
PG  - 3323-3329
AB  - AIM: Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are 
      common methods for assessment of human epidermal growth factor receptor 2 (HER2) 
      in breast cancer. MATERIALS AND METHODS: In a cohort of 498 consecutive patients 
      with breast cancer, we examined concordance between IHC and FISH for HER2 on 
      tissue microarray (TMA) sections. In a subset of 116 specimens, we examined HER2 
      concordance from the block used for diagnostics and a randomly-chosen additional 
      block (a proxy of the core biopsy). RESULTS: Overall concordance between both 
      methods on TMA sections was 93.8% and between HER2, determined on diagnostic and 
      additional blocks, was 93.6% for IHC and 98.0% for FISH. CONCLUSION: Since some 
      cases were discordant, we suggest that both methods be used for HER2 assessment. 
      The lower concordance rate between diagnostic and additional blocks using IHC 
      compared to FISH suggests a greater variability of IHC staining across tumor 
      regions than for FISH results.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Furrer, Daniela
AU  - Furrer D
AD  - Cancer Research Center at Laval University, Faculty of Medicine, Laval 
      University, Quebec City, Canada.
AD  - Oncology Axis, CHU of Quebec Research Center, Laval University, Quebec City, 
      Canada.
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Laval 
      University, Quebec City, Canada.
FAU - Jacob, Simon
AU  - Jacob S
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, Canada.
AD  - Pathology Service, Saint-Sacrement Hospital, Quebec City, Canada.
AD  - Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of 
      Medicine, Laval University, Quebec City, Canada.
FAU - Caron, Chantal
AU  - Caron C
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, Canada.
AD  - Pathology Service, Saint-Sacrement Hospital, Quebec City, Canada.
FAU - Sanschagrin, Francois
AU  - Sanschagrin F
AD  - Oncology Axis, CHU of Quebec Research Center, Laval University, Quebec City, 
      Canada.
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, Canada.
FAU - Provencher, Louise
AU  - Provencher L
AD  - Cancer Research Center at Laval University, Faculty of Medicine, Laval 
      University, Quebec City, Canada.
AD  - Oncology Axis, CHU of Quebec Research Center, Laval University, Quebec City, 
      Canada.
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, Canada.
AD  - Department of Surgery, Faculty of Medicine, Laval University, Quebec City, 
      Canada.
FAU - Diorio, Caroline
AU  - Diorio C
AD  - Cancer Research Center at Laval University, Faculty of Medicine, Laval 
      University, Quebec City, Canada caroline.diorio@crchudequebec.ulaval.ca.
AD  - Oncology Axis, CHU of Quebec Research Center, Laval University, Quebec City, 
      Canada.
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, Laval 
      University, Quebec City, Canada.
AD  - Deschenes-Fabia Center for Breast Diseases, Saint-Sacrement Hospital, Quebec 
      City, Canada.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*analysis/*genetics
MH  - Biopsy, Large-Core Needle
MH  - Breast Neoplasms/*enzymology/*genetics
MH  - Female
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*analysis/*genetics
MH  - Reproducibility of Results
MH  - *Tissue Array Analysis
OTO - NOTNLM
OT  - ASCO/CAP guidelines
OT  - Breast neoplasms
OT  - HER2 status
OT  - biopsy
OT  - multiple blocks
OT  - trastuzumab
EDAT- 2017/05/30 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/29 06:00
PHST- 2017/03/31 00:00 [received]
PHST- 2017/04/16 00:00 [revised]
PHST- 2017/04/19 00:00 [accepted]
PHST- 2017/05/29 06:00 [entrez]
PHST- 2017/05/30 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - 37/6/3323 [pii]
AID - 10.21873/anticanres.11701 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Jun;37(6):3323-3329. doi: 10.21873/anticanres.11701.